Pancreatic ductal adenocarcinoma carries a five-year survival rate of roughly 3% at the metastatic stage, which makes the regulatory momentum now building around daraxonrasib worth watching closely. The European Medicines Agency’s Committee for Medicinal Products for Human Use has initiated a phased review of daraxonrasib for previously treated metastatic PDAC, evaluating data in real time rather than waiting for a complete marketing authorization application. That procedural choice reflects genuine regulatory urgency, not routine processing. The drug also carries EMA orphan designation and has been flagged as high priority under the agency’s Cancer Medicines Pathfinder project, which launched in 2023 to accelerate medicines with meaningful unmet-need potential.
What separates this moment from earlier RAS-inhibitor enthusiasm is the trial data underneath it. The pivotal Phase 3 RASolute 302 study, presented at ASCO 2026 and simultaneously published in the New England Journal of Medicine, showed statistically significant improvements in both overall survival and progression-free survival against standard cytotoxic chemotherapy in patients with previously treated metastatic PDAC, regardless of whether a specific RAS mutation was identified. Patient-reported outcomes reinforced the signal: daraxonrasib delayed deterioration in cancer-related pain, global health status, and quality of life. Those endpoints matter to regulators. Quality-of-life deterioration in pancreatic cancer is rapid and measurable, so durable delay on those metrics strengthens the clinical story considerably.
The regulatory picture on both sides of the Atlantic is tightening simultaneously. Revolution Medicines is nearing completion of its rolling NDA submission to the FDA under the Commissioner’s National Priority Voucher pilot program, a review-acceleration pathway announced in June 2025 for products aligned with U.S. national health priorities. Daraxonrasib holds FDA Breakthrough Therapy Designation and Orphan Drug Designation for previously treated metastatic PDAC with G12 mutations. The Phase 3 program is broader still, with three additional registrational trials enrolling in PDAC and RAS-mutant non-small cell lung cancersmall cell lung cancer. Current approved second-line options for metastatic PDAC remain limited, with chemotherapy regimens including the NALIRIFOX regimen anchoring standard care in the first-line setting and no molecularly targeted agent yet approved for second-line disease.
The specific marker to track now is the FDA rolling submission completion date. Once the NDA is submitted in full, the Priority Review clock starts, and that timing will determine whether a U.S. approval precedes or follows EMA action. A near-simultaneous approval in both major markets, driven by the same Phase 3 dataset, would be a clinical and commercial inflection point for the entire RAS-inhibitor field.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
